PLGA Acid Capped (PLGA-COOH, 85:15)

Price range: $100.00 through $400.00

PLGA Acid Capped (PLGA-COOH, 85:15) is a biodegradable poly(lactide-co-glycolide) copolymer with an 85:15 lactide ratio and a terminal carboxylic acid (COOH) group. The free carboxyl end group enables efficient bioconjugation and chemical modification, while the high lactide content provides slower degradation and prolonged drug release. PLGA-COOH (85:15) is widely used in sustained-release drug delivery, nanoparticle formulation, tissue engineering, and biomaterials research.

Product Name: PLGA Acid Capped (PLGA-COOH, 85:15)
Alternative Name: Carboxyl-Terminated PLGA (85:15), PLGA-COOH (85:15)
Polymer Type: Poly(D,L-lactide-co-glycolide)
Lactide Ratio: 85:15
Molecular Weight: 2k, 5k, 10k, 15k, 20k, 30k, 50k, 100k Da, Custom
End Group: Carboxylic Acid (COOH)
Appearance: White to off-white powder or solid
Solubility: Dichloromethane, Chloroform, THF, Acetone, DMF, DMSO
Storage: -20°C, dry and protected from moisture
Purity: Typically ≥95%

Description

General Description

PLGA Acid Capped (85:15) is a carboxyl-terminated biodegradable polyester composed of 85% lactide and 15% glycolide. Compared with PLGA 50:50 and 75:25, the higher lactide content increases hydrophobicity and significantly slows polymer degradation, making this composition particularly suitable for long-term drug release and implantable biomedical applications.

The terminal carboxylic acid group provides a versatile reactive handle for conjugation with polyethylene glycol (PEG), peptides, proteins, antibodies, fluorophores, and targeting ligands using carbodiimide (EDC/NHS) coupling chemistry. As a result, PLGA-COOH (85:15) is widely used as a precursor for functional PLGA derivatives and targeted drug delivery systems.

PLGA Acid Capped (85:15) is extensively employed in nanoparticles, microspheres, injectable depots, implantable devices, tissue engineering scaffolds, and controlled-release formulations requiring prolonged degradation profiles.

Applications

  • Sustained drug delivery
  • Long-acting injectable formulations
  • Nanoparticle formulation
  • Microsphere preparation
  • Implantable drug delivery systems
  • PEG conjugation
  • Protein conjugation
  • Tissue engineering
  • Biomaterials development
  • Biomedical research

Features and Benefits

  • Terminal carboxylic acid functionality
  • 85:15 lactide composition
  • Slower degradation profile
  • Extended drug release
  • Compatible with EDC/NHS coupling chemistry
  • Excellent biocompatibility
  • Excellent drug encapsulation capability
  • Available in multiple molecular weights
  • Ideal precursor for PLGA conjugates

Additional information

Molecular weight

2000, 5000, 10K, 20K, 40K

Package size

1g, 5g